Response Biomedical Corp

Response Biomedical Corp specializes in in vitro diagnostic (IVD) devices focused on cardiac and respiratory testing. Their products include rapid immunoassay kits for detecting cardiac markers like troponin I, myoglobin, CK-MB, and NT-proBNP, as well as controls and fluorescent immunoassay analysers for point-of-care use. They also produce RSV antigen detection kits and controls, designed for quick clinical results in healthcare settings.

Response Biomedical Corp is headquartered in the United States. The company’s location aligns with its focus on serving US healthcare providers and regulatory requirements.

Response Biomedical Corp’s devices are listed in the FDA’s Unique Device Identification (UDI) system. This registry ensures traceability and compliance tracking for Class I in vitro diagnostic devices under US regulations.

Response Biomedical Corp’s devices fall under Class I classification in the US. This classification applies to low-risk in vitro diagnostics, including rapid test kits, controls, and analysers for cardiac and respiratory markers. Class I devices typically undergo general controls but may require additional oversight depending on their specific use.

The primary purpose of Response Biomedical Corp’s IVD devices is to enable rapid, point-of-care testing for critical cardiac and respiratory conditions. Their products, such as troponin I and RSV antigen kits, are designed for quick detection in clinical settings, helping healthcare providers make timely diagnostic decisions without delays.